Medically reviewed by Dr. Anjmun Sharma, MD | Updated 2026-07-164 min read

Compounded or brand-name GLP-1: an informed decision guide

Approved brand products and compounded preparations are not equivalent. A useful discussion starts with indication, medical need, product evidence, and options that can be filled legally for your location.

Quick answerAn approved brand drug has evidence and regulatory review for that finished product. A compounded preparation is a different prescription, not FDA-approved and not brand-identical. Outcome claims should not be transferred between them.

Five differences that change the decision

TopicApproved brandCompounded preparation
FDA reviewFinished product approved for specific indications.Finished preparation is not approved.
EvidenceTrials of the studied product.Cannot claim brand results as its own.
PresentationApproved labeling defines presentation and use.Prescription and instructions may vary by pharmacy.
DispensingLicensed pharmacy.Licensed pharmacy under applicable requirements.
CostDepends on coverage, product, and manufacturer program.Depends on prescription and pharmacy; evaluation is billed separately.

Brand evidence is not a compounded promise

Published weight-loss percentages come from trials with defined products, doses, and follow-up protocols. They help explain the treatment studied but do not predict the outcome of a different preparation. Every result varies.

Still comparing?

Test the compounded option for one month, $199, before you commit

The Skeptics' Trial includes the physician evaluation and, only if a prescription is approved and the dispensing pharmacy can fulfill it for your location, one month of compounded semaglutide; the pharmacy confirms packaging and shipping details before fulfillment. No long-term commitment. A compounded preparation is a different product from Wegovy or Ozempic: not FDA-approved, not brand-identical, and results vary.

How the 30-day trial works

When a preparation may be considered

FDA states that compounding may be appropriate when an individual patient's medical need cannot be met by an available approved drug. That conclusion must be individualized. Cost, general preference, or convenience language does not replace the required clinical determination.

A calm decision checklist

For an expanded table, see our main compounded and brand-name GLP-1 comparison.

Expanded decision guide

Start by separating the categories

An FDA-approved brand product is a specific finished drug with product-specific labeling and reviewed evidence. A compounded GLP-1 preparation is made under a compounding pathway for an identified clinical circumstance. It is not FDA-approved, not brand-identical, results vary, and it should not be described with the approved product's outcome claims.

Practical questionApproved productCompounded preparation
What evidence applies?The exact label and product-specific studiesThe finished preparation has not received FDA premarket approval
Why might it be used?It fits the indication and individual planA prescriber identifies a clinical rationale and separately confirms the applicable legal conditions
What must be verified?Prescription, product, pharmacy, cost, and follow-upAll of those items plus the compounding reason and dispensing-pharmacy record

Why compounding exists and how 503A fits

Compounding can address an individual need that an available approved product cannot meet. Under 503A, qualifying compounding may be performed by a licensed pharmacist in a state-licensed pharmacy or federal facility, or by a licensed physician. The clinic performs the medical evaluation but does not manufacture or dispense; any fulfillment depends on a dispensing pharmacy verified for the patient and location. If the significant-difference exception is relied on, the prescriber must determine and document that a change produces a significant difference for the identified patient. Changing a concentration or adding an ingredient does not establish that result automatically.

When each route may fit

An approved product may fit when its indication, product-specific studies, formulation, access, and risk profile align with the patient. A compounded preparation may be discussed when the prescriber identifies a relevant clinical rationale and lawful dispensing is possible. Clinical fit does not replace the separate compounding conditions. Either decision requires informed consent, side-effect planning, and follow-up.

Warning signs before payment

Primary and official source trail

Read each source for the exact product, population, date, method, and limitation. A source supports only the claim it actually studied or the policy it actually states.

Apply this checklist to New Hope

Every standard on this page is one we hold ourselves to: a $119 physician review with Dr. Anjmun Sharma, MD before any prescription decision, a named dispensing pharmacy you can verify for your location, transparent pricing with medication billed separately (compounded semaglutide from $166/month, tirzepatide from $233/month), and plain disclosure that compounded medications are not FDA-approved, not brand-identical, and that results vary. Telehealth care is available for eligible California patients.

See if you qualify, free 2-min quiz Check availability for your location

Frequently asked questions

Does a compounded GLP-1 have the same evidence as the brand drug?

No. Trials support the product and formulation studied. They do not establish effectiveness or predict the outcome of a different compounded preparation.

Is compounded semaglutide identical to Wegovy or Ozempic?

No. It is not FDA-approved, not brand-identical, and results vary by individual.

What matters besides price?

Indication, contraindications, availability of an approved drug, individual need, administration experience, follow-up, and the pharmacy that would dispense all matter.

Who dispenses a compounded preparation?

The licensed pharmacy, not the clinic, prepares and dispenses the prescription when applicable requirements are met.

How are costs separated?

The medical evaluation is $119 if care is available for your location. Medication is quoted separately before you proceed.

This article is educational and does not replace an individual medical evaluation. Do not start, stop, or change a medication without speaking with your health care professional.

Wegovy and Ozempic are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. New Hope Weight Loss is not affiliated with or endorsed by these companies. Compounded semaglutide and tirzepatide are not FDA-approved, not brand-identical, and results vary by individual.

Not ready to start? Get the details by email.

Pricing, how it works, and what to expect, sent to your inbox. No pressure, unsubscribe anytime.